Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
169. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL,<br />
Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D,<br />
Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC 2005 Preoperative<br />
gefitinib versus gefitinib and anastrozole in postmenopausal patients with<br />
oestrogen-receptor positive and epidermal-growth-factor-receptor-positive<br />
primary breast cancer: a double-blind placebo-controlled phase II randomised<br />
trial. Lancet Oncol 6:383-91<br />
170. Winer E, Cobleigh MA, Dickler M, Miller K, Fehrenbacher L, Jones C,<br />
Justice R 2002 Phase II multicenter study to evaluate the efficacy and safety of<br />
Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced<br />
or metastatic breast cancer. Breast Can. Res. Treat. 76:A445<br />
171. Rusnak DW, Lackey K, Affleck K, Wood <strong>ER</strong>, Alligood KJ, Rhodes N, Keith<br />
BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM 2001 The effects of the<br />
novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase<br />
inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines<br />
in vitro and in vivo. Mol Cancer Ther 1:85-94<br />
172. Spector NL, Xia W, Burris H, 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B,<br />
Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A,<br />
Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S 2005<br />
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and<br />
ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with<br />
advanced malignancies. J Clin Oncol 23:2502-12<br />
67